HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC proposed settlement

This article was originally published in The Rose Sheet

Executive Summary

Thomas Fenton agrees to settle charges that he made false and unsubstantiated claims in an infomercial produced by Synchronal promoting Omexin as a baldness cure. The proposed settlement would prohibit Fenton from distributing the "Can You Beat Baldness?" infomercial, misrepresenting a commercial as an independent program, and making any future unsubstantiated claims for any food, drug or device. Fenton is the last party to settle a 1991 FTC complaint regarding claims made for Omexin and the Anushka Bio-Response Body Contouring Program. All of the other respondents settled with FTC June 3 ("The Rose Sheet," June 7, p. 1). In October, FTC amended its complaint against Fenton, limiting the allegations to the Omexin infomercial

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel